Trials & Approvals
Availability of C2N’s First Blood-Based Diagnostic Marks Breakthrough in Alzheimer’s Disease
2020-10-30
Foundation Medicine’s CGP Test FDA Approved as Companion Diagnostic for Bayer’s Tumor Agnostic Therapy
2020-10-26
First to the Finish Line! Remdesivir Becomes the First and Only FDA Approved Drug to Treat COVID-19
2020-10-23
Regeneron’s FDA Success with Ebola Treating Antibody Cocktail, Inmazeb, Bodes Well for its COVID-19 Candidate
2020-10-16
Lilly’s Investigational Monoclonal Antibody Registers Symptom Improvement in Crohn’s Disease Patients
2020-10-13
LATEST
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115